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INTRODUCTION
Providing full medical support enhancing 
the recovery is crucial for patients suffering from 
sepsis. Optimal intensive care requires correction 
of disbalance produced by the septic condition. 
Elevated blood glucose even in patients without 
diabetes mellitus is one of the most frequent findings 
with numerous adverse effects. 
PATHOGENESIS OF SEPSIS
In septic patients pathogens’ invasion threatens 
homeostasis. As a sophisticated and self-organized 
unit the human body responses to the threat by means 
of an adaptive mechanism first described by Hans 
Selye in 1936. First, vital organs such as brain, heart, 
and kidneys are energy-supplied with great priority. 
This secondarily increases the options for handling 
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the invasion. The ultimate goal is restoration of the 
metabolic balance. Deeper insight into this response 
reveals a complicated cascade of neuroendocrine 
and proinflammatory changes. This results in an 
increase of circulating cytokines as interleukin (IL)-
1, IL-6, tumour necrosis factor (TNF)-α, macrophage 
migration inhibitory factor (MIF), free radicals, nitric 
oxide (NO) having deleterious effects on coagulation 
cascade, cardiovascular system, kidneys, lungs, liver, 
central nervous system, and gastrointestinal tract 
and leads to multiorgan dysfunction. 
The pathophysiologic mechanism causes 
changes in carbohydrate metabolism such as insulin 
resistance, induction of glycogenolysis in the liver 
and increase of glyconeogenesis. This is the reason 
why even non-diabetes mellitus patients with sepsis 
develop hyperglycemia. 
The inflammatory mediators may overcome 
the normal physiology of down regulation of GLUT-
transporters in hyperglycemia, which exposes 
cell to high uptake of glucose and glucose toxicity, 
respectivelly. This causes hyperglycemia-induced 
mitochondrial abnormalities observed in liver and 
skeletal muscle. Superoxide production is increased 
in hyperglycemia. That leads to nitration of majority 
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of the mitochondrial complexes and voltage-
dependent anion channels. High blood glucose (BG) 
impairs neutrophil chemotaxis and phagocytosis 
and decreases microvascular responsiveness (4,8).
 
INSULIN IN SEPSIS
Beneficial effects of insulin therapy in sepsis 
may originate from achieving normal BG levels or 
the insulin itself, or both. Detrimental hyperglycemia 
effects are reduced or avoided in euglycemia. On the 
other hand, insulin acts as a powerful anabolic and 
antiinflammatory agent suppressing the production 
of IL-1, IL-6, MIF, reversing endothelial dysfunction 
and stimulating production of antiinflammatory 
factors IL-4 and IL-10. 
Goals of glycemic control
Normal BG levels are strongly recommended in 
critically ill and particularly septic patients. It is well-
documented that hyperglycemia in these subjects is 
associated with higher infection rates, higher overall 
morbidity and mortality. A large study proved that 
each 1 mmol/L increase in BG level is associated with 
6-10% increased relative risk of pneumonia, urinary 
tract or skin infections. In 2007, Van den Berghe 
suggested that a range between 4,4 mmol/L and 6,1 
mmol/L should be targeted for intensive care patients 
(18). According to the 2008 international guidelines, 
target BG level should be below 8,3 mmol/L (5). 
Normoglycemia is not the only goal regarding 
glycemic control. Of great importance is also 
maintaining stable BG concentration. Variations 
of glucose levels are a significant and independent 
predictor of mortality and even stronger predictor 
of intensive care unit (ICU) mortality than mean BG 
concentration (1,6,17). 
Coagulation cascade
Activating the endothelium through 
proinflammatory mediators unleashes a 
procoagulant state that can lead to disseminated 
intravascular coagulation. Hyperglycemia itself 
enhances coagulation and attenuates fibrinolytic 
activity. 
Myocardial function
Myocardial depression is frequent in patients 
with sepsis. Moreover, this dysfunction is not related 
to BG concentrations and is completely reversible 
by intraarterial insulin infusions despite various 
BG concentrations. This leads to the conclusion 
that it is insulin that improves cardiac performance 
irrespective of BG levels (4). 
Lipid metabolism
Critical disease is associated with lipid disorders, 
including increase of triglycerides and reduction 
of high-density lipoproteins. Insulin reverses this 
disbalance. Elevated free fatty acids are also proved 
to decline during insulin therapy (3). 
Renal function
Sepsis is responsible for acute kidney injury 
in several mechanisms including afferent arteriolar 
vasoconstriction and/or efferent arteriolar 
vasodilatation, endotoxin and inflammatory 
mediators’ injury, and glomerular microthrombi. 
Data show that intensive insulin therapy for 
hyperglycemic critically ill patients may help in 
preventing the kidney injury. Anyway, the so 
important fluid resuscitation should be performed 
with caution because of the possible deleterious effect 
of colloids on already impaired renal function (2). 
Liver function
The reduced need of blood product transfusions 
may improve erythropoiesis or reduce hemolysis, 
since this benefit is associated with a lower incidence 
of hyperbilirubinemia. Intensive insulin therapy 
may reduce the risk of cholestasis, since adequate 
provision of glucose and insulin to hepatocytes is 
crucial for normal choleresis.
Intestinal function
Animal studies prove that insulin reduces the 
microcirculatory dysfunction in sepsis through 
lowering the platelet activating factor (PAF), PGI-2 
and, especially, TxA2. 
GLYCEMIC CONTROL IN SEPSIS
Alternatives
Two main alternatives of insulin therapy in 
ICU settings are intensive insulin treatment (IIT) 
and conventional insulin therapy (CIT). Significant 
controversies around the world regarding glycemic 
control originate from the very definition of IIT. The 
great number of publications consider both methods 
as intravenous insulin infusion with different target 
BG levels (4,5-6,0 mmol/L in IIT and <10 mmol/L 
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in CIT) (7). In contrast, some substantial documents 
as the recently published Clinical Practice Guideline 
From the American College of Physicians define IIT 
as ‘use of intravenous insulin to achieve targeted 
blood glucose level with frequent blood glucose 
testing and adjustment of insulin doses’ with targets 
of 4,4-6,1 mmol/L for ICU and <11,1 mmol/L for 
non-ICU patients (14) without defining CIT.
The era before Leuven
Before 2001, no confirmation existed about the 
actual benefits of IIT in critically ill patients. They 
were subjected either to IIT, or to CIT according to 
institutional protocols or individual judgement.
Van den Berghe’s Study
In 2001, Van den Berghe published his Leuven 
study of IIT in critically ill patients (19). His results 
showed reduced ICU and overall hospital mortality, 
more substantial for septic patients, lower rates of 
bloodstream infections, renal failure, blood product 
transfusions and shorter mechanical ventilation 
times. Because of these favourable conclusions 
this study became an international cornerstone for 
glycemic control in ICU. With time, some of these 
IIT advantages were proved and other emerged 
including reduction of fibrinolytic impairment 
(15), hepatoprotective effect after hepatic surgery, 
improved insulin sensitivity (11) and even economic 
benefit. 
Unfortunatelly, subsequent large trials failed 
to confirm most of Van den Berghe’s results. In 
2008 and 2009, two large trials were suspended 
because of higher rates of adverse effects including 
hypoglycemia and mortality (13). Another large 
study (7) showed similar results. This led to still 
ongoing debates regarding the most appropriate 
glucose control method in this patients’ population. 
The reasons for these discrepancies may be 
found in the design of Van den Berghe’s study. Most 
patients were after coronary bypass surgery. They 
were given intravenous loads of glucose (200 to 300 
g/24 hours) and it was possible that IIT decreased 
this glucose load’s adverse effects and, vise versa, this 
glucose load lowered the number of hypoglycemic 
events (7). What is more,Van den Berghe used total 
parenteral nutrition with his patients which also 
caused hyperglycemia and may have raised the 
mortality rate in the control arm. 
One of the main concerns regarding IIT is the 
higher hypoglycemia rates, especially during the first 
24 hours. Reported rates are different and depend on 
the actual protocol used and blood sample site (arterial 
versus capillary or venous). They are, however, always 
significant in IIT and independent prognostic factor 
for adverse effects or death. A severe hypoglycemic 
event (BG <2,2 mmol/L) means a six-fold increase 
in mortality (9). The number of hypoglicemias is 
higher in patients receiving intravenous insulin than 
in those receiving subcutaneous insulin. Duration of 
time spent in ICU is a strong predisposing factor for 
hypoglycemia in surgical critically ill patients. Other 
factors include prolonged renal replacement therapy 
and inotropic and vasopressor therapy (20). 
The severity of sepsis is also a crucial factor 
regarding the rates of hypoglycemic events. Waeschle 
et al. find frequencies of 2,1%, 6% and 11,5% in 
non-severe sepsis, severe sepsis and septic shock, 
respectively (20). 
This motivated the Surviving Sepsis Campaign 
Guidelines (5) and its Additional Statement on 
glucose control to recommend insulin therapy for 
BG over 10 mmol/L with target levels of <8,3 mmol/L 
as mentioned above. Although widely debated 
these documents remain the current specific sepsis 
treatment guidelines.
Of course, success or failure of glycemic control 
is always somewhat influenced by the comedication 
in the individual patient. Certain drugs such as 
ACE-inhibitors or chlorpromazine can cause drop 
of BG levels and, eventually, hypoglycemia. Other 
drugs such as adrenalin, noradrenalin, β-agonists, 
corticosteroids, diuretics, theophylline, isoniazid, 
and phenytoin cause hyperglycemia. Administration 
regimen also influences the glycemia. A prospective 
randomized trial of Loisa et al. concluded that if the 
recommended corticosteroid therapy for septic shock 
is given by continuous infusion then normoglycemia 
is more easily achieved.
Even if IIT is the method of choice there is 
no uniformity in the actual protocols for glycemic 
control. Various more or less widely used protocols 
exist and each of them has its advantages and 
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disadvantages. Differences include insulin delivery 
and adjustments, time to target BG levels and 
strategy regarding individual insulin resistance. 
Comparing several protocols and stating that each 
patient would benefit differently from any of them 
it was concluded that a single institutional protocol 
would be an advantage in terms of uniformity but it 
was not realistic. 
RECENT ADVANCES AND ADDITIONAL 
OPTIONS
The majority of algorithms used for adjustment 
of insulin delivery include frequent blood sampling 
(every 1 to 4 hours) and bedside calculation of the 
insulin dosage. An attractive alternative may be the 
computerized software systems like Glucommander. 
Still a recent study on Glucommander use in critically 
ill patients showed more than twofold increase in 
hypoglycemia rates.
Glycemic control could be further improved by 
implementation of continuous or near-continuous 
monitoring of BG levels using intravascular or 
subcutaneous (tissue) glucose sensors. Interestingly, 
Lorencio et al. recently found out a better accuracy of 
real-time continuous glucose monitoring in patients 
with septic shock (12). 
Another option is the continuous subcutaneous 
insulin infusion (CSII) - a successful insulin-pump 
method for type 1 diabetes mellitus patients. 
Outcomes of IIT also depend on the nutritional 
support chosen. It was recently proved that 
permissive underfeeding (60-70% of calculated daily 
caloric needs) was beneficial compared to standard 
feeding protocols as it lowered the mortality rates 
and mechanical ventilation duration. 
It is possible that one of the keys towards safer 
IIT with lower rates of hypoglycemia is the route of 
feeding administration. Current clinical nutrition 
guidelines recommend enteral nutrition (EN) for all 
the patients who are not expected to be on a full oral 
diet within 3 days. Benefit of immune-modulating 
formulae (enriched in arginin, nucleotides and ώ-3 
fatty acids) is proven in mild sepsis, reducing the 
number of bacteriemias and mortality but is unclear 
or even potentially harmful and, therefore, not 
recommended in severe sepsis (10). 
On the other hand, EN is often associated 
with low amount of energy delivered. In such cases 
or when other obstacles occur adding parenteral 
nutrition (PN) to EN might be a tempting alternative 
but evidence is still insufficient for recommendation 
(16). It should be noted that EN is more frequently 
related to hypoglycemic events than total PN and 
mixed nutrition could be a way to reduce relevant 
hypoglycemias. PN is associated with higher risk 
of fungal and other superimposed bloodstream 
infections, too.
CONCLUSION
Although still controversial, intensive insulin 
therapy is the most widely used glycemic control 
method in ICU and, specifically, in septic patients. 
Negative impact of hyperglycemia is well-known 
and successfully avoided, but at the expense of 
unacceptable rates of hypoglycemic events despite 
recent advances in insulin administration and 
glucose monitoring. Because glycemic control 
is multifactorial, perhaps, the correct strategy is 
combined approach with computerized infusion, 
continuous BG monitoring and proper feeding 
support being the missing pieces in this sweet puzzle. 
Large statistically powered studies are necessary to 
provide the evidence-based medicine proof. 
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